Compare KITT & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KITT | SBFM |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 7.2M |
| IPO Year | N/A | N/A |
| Metric | KITT | SBFM |
|---|---|---|
| Price | $0.90 | $1.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 7.1M | 57.6K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $4,688,840.00 | ★ $37,323,742.00 |
| Revenue This Year | $2,936.06 | $10.26 |
| Revenue Next Year | N/A | $32.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 95.38 | 13.24 |
| 52 Week Low | $0.69 | $1.16 |
| 52 Week High | $54.36 | $3.90 |
| Indicator | KITT | SBFM |
|---|---|---|
| Relative Strength Index (RSI) | 45.97 | 51.30 |
| Support Level | $0.69 | $1.16 |
| Resistance Level | $1.10 | $1.40 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 50.94 | 71.73 |
Nauticus Robotics Inc develops fully electric autonomous robotic solutions for subsea applications. The company's business model includes using robotic systems for service, selling vehicles and components, and licensing related software to both the commercial and defense business sectors. The company's addressable markets include upstream, midstream, and downstream oil and gas, defense, offshore renewables, seafloor telecommunications, aquaculture, port security, oceanographic research, and subsea mining.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.